Venerable Carlo Acutis. / carloacutis.com.
Rome, Italy, May 3, 2021 / 13:00 pm (CNA).
Catholic parishes across Italy and as far away as the Philippines celebrated what would have been the 30th birthday of Blessed Carlo Acutis on Monday.Acutis, w.
Ferentino Tyre opens Sri Lanka plant; eyes exports to U.S., Europe
Print
HORANA, Sri Lanka Ferentino Tyre Corp. Pvt. Ltd., an enterprise backed by United Arab Emirates-based investment company Onyx Group, has commissioned production at a $250 million factory at a site southwest of Colombo.
The project dates to January 2017, when the company previously known as Rigid Tyre Corp. (Pvt.) Ltd. disclosed plans to build the plant in an industrial park in Horana, using equipment acquired from Italy s Marangoni Group.
The company did not explain the reasons for the name change, but it promotes its Italian heritage on its website.
“We have continued to invest strategically in capacity, technology and expertise across our global network so we can accelerate innovation and enhance productivity for our customers,” Mike Shafer, senior vice president and president, pharma service for Thermo Fisher Scientific, said in a recent release. “This has enabled us to respond quickly and support our customers with unprecedented scale and depth of capabilities to meet high demand for new therapies and vaccines. By simplifying the supply chain and solving complex manufacturing challenges, we shorten development timelines in order to get high-quality medicines to patients faster.”
The company will expand its plants in Greenville, NC, Swindon, UK, and Ferentino and Monza in Italy. New assets will support the development of sterile drug products and the production of medicines, therapies, and vaccines.
Subscribe
Thermo Fisher to build new California plasmid DNA production site, expands pharma services and sterile drug manufacturer footprint in EU and US By Jane Byrne Thermo Fisher Scientific today announced the construction of a new cGMP plasmid DNA manufacturing facility at its site in Carlsbad, California.
The site will expand the CDMO s clinical and commercial capabilities for cGMP plasmid DNA used as a critical raw material to develop and manufacture cell and gene-based therapies including cancer treatments as well as mRNA vaccines.
In addition, Thermo Fisher said the site will have the capability to produce large-scale plasmid DNA as a primary drug substance for DNA therapies. As the global plasmids market continues to grow rapidly, this expansion will provide much needed capacity to the industry, it confirmed.
The company’s new manufacturing assets will support the development of sterile drug products and boost production.
Waltham, MA-based Thermo Fisher Scientific is moving to expand its manufacturing footprint in Europe and North America with the addition of 15 new development and cGMP production lines at four of its facilities.
“We have continued to invest strategically in capacity, technology and expertise across our global network so we can accelerate innovation and enhance productivity for our customers,” Mike Shafer, senior vice president and president, pharma service for Thermo Fisher Scientific, said in a recent release. “This has enabled us to respond quickly and support our customers with unprecedented scale and depth of capabilities to meet high demand for new therapies and vaccines. By simplifying the supply chain and solving complex manufacturing challenges, we shorten development timelines in order to get high-quality medicines to patients faster.”